Pteryxin suppresses osteoclastogenesis and prevents bone loss via inhibiting the MAPK/Ca2+ signaling pathways mediated by ROS
Osteoporosis, as a severe public health problem worldwide, causes systemic damage to bone mass, strength, and microstructure with an increased propensity for fragility fractures. Given the inherent adverse effects associated with long-term use of current prescription medications for osteoporosis tre...
Main Authors: | Ran Sun, Na Hai, Biao Yang, JunChun Chen, Jing Li, Qiufei Li, Jinmin Zhao, Jiake Xu, Qian Liu, Bo Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-09-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332223006881 |
Similar Items
-
Biological potential and therapeutic effectiveness of pteryxin in medicine. A viable alternative to current remedies for the treatment of human disorders
by: Kanika Patel, et al.
Published: (2024-03-01) -
Isosinensetin alleviates estrogen deficiency-induced osteoporosis via suppressing ROS-mediated NF-κB/MAPK signaling pathways
by: Yiwu Qin, et al.
Published: (2023-04-01) -
Cytoprotective Effect of Pteryxin on Insulinoma MIN6 Cells Due to Antioxidant Enzymes Expression via Nrf2/ARE Activation
by: Junsei Taira, et al.
Published: (2023-03-01) -
Pharmacology-based molecular docking of 4-methylcatechol and its role in RANKL-mediated ROS/Keap1/Nrf2 signalling axis and osteoclastogenesis
by: Yang Xu, et al.
Published: (2023-03-01) -
Oxymatrine Attenuates Osteoclastogenesis via Modulation of ROS-Mediated SREBP2 Signaling and Counteracts Ovariectomy-Induced Osteoporosis
by: Chao Jiang, et al.
Published: (2021-05-01)